MARKET

RVNC

RVNC

Revance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.24
-0.07
-0.27%
Opening 13:33 08/14 EDT
OPEN
24.13
PREV CLOSE
24.30
HIGH
24.44
LOW
23.75
VOLUME
71.70K
TURNOVER
--
52 WEEK HIGH
27.97
52 WEEK LOW
9.88
MARKET CAP
1.60B
P/E (TTM)
-5.7493
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RVNC stock price target is 35.20 with a high estimate of 55.00 and a low estimate of 23.00.

EPS

RVNC News

More
Revance Therapeutics Highlights 2 Peer-Reviewed Publications Reporting Safety, Efficacy Results From SAKURA 3 Open-Label Safety Study In Dermatologic Surgery
Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its investigational neuromodulator product, DaxibotulinumtoxinA for Injection, today
Benzinga · 3d ago
Revance Therapeutics EPS misses by $0.12, misses on revenue
Revance Therapeutics (NASDAQ:RVNC): Q2 GAAP EPS of -$1.12 misses by $0.12. Revenue of $0.3M misses by $0.11M. Press Release
seekingalpha · 08/07 01:31
Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update
Revance Reports Second Quarter 2020 Financial Results, Provides Corporate Update
Business Wire · 08/06 20:05
Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Revance to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020
Business Wire · 07/30 20:05
Revance finalizes HintMD acquisition
Revance Therapeutics (NASDAQ:RVNC) has completed its acquisition of privately-held Hint, Inc. doing business as HintMD. The Company has issued a total of 8
seekingalpha · 07/24 11:58
Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices
Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices
Business Wire · 07/23 22:20
Is Revance Therapeutics Inc (RVNC) Going to Burn These Hedge Funds?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 07/05 19:28
Revance Positive Data And Other News: The Good, Bad And Ugly Of Biopharma
Seeking Alpha - Article · 07/03 06:07

Industry

Biotechnology & Medical Research
-0.69%
Pharmaceuticals & Medical Research
-0.36%

Hot Stocks

Symbol
Price
%Change

About RVNC

Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. It evaluates DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in three therapeutic indications: cervical dystonia, adult upper limb spasticity and plantar fasciitis. It has a portfolio of products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and HintMD fintech platform. The RHA Collection of dermal fillers is a filler for correction of dynamic facial wrinkles and folds. HintMD fintech platform includes integrated smart payment, subscription and loyalty digital services.
More

Webull offers kinds of Revance Therapeutics Inc stock information, including NASDAQ:RVNC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RVNC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RVNC stock methods without spending real money on the virtual paper trading platform.